Financials data is unavailable for this security.
View more
Year on year Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd 's revenues fell -16.61% from 850.73m to 709.40m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 108.63m to 39.73m, a -63.42% decrease.
| Gross margin | 88.90% |
|---|---|
| Net profit margin | -8.83% |
| Operating margin | -13.68% |
| Return on assets | -2.47% |
|---|---|
| Return on equity | -2.72% |
| Return on investment | -2.70% |
More ▼
Cash flow in CNYView more
In 2024, cash reserves at Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd fell by 139.61m. In addition, the company used more cash to support its operations than it earned, posting a cash flow loss of 16.51m. In addition the company used 22.14m on investing activities and also paid 101.27m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 2.18 |
|---|---|
| Tangible book value per share | 2.12 |
More ▼
Balance sheet in CNYView more
| Current ratio | 8.68 |
|---|---|
| Quick ratio | 8.51 |
| Total debt/total equity | 0.0071 |
|---|---|
| Total debt/total capital | 0.007 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -28.57% and -63.51%, respectively. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
| Div yield(5 year avg) | 0.55% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -31.07 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -160.57 |
More ▼
